Academic vs. Industry: Why Non-Industry Trials Are Failing to Reach the Finish Line

MedXY Editorial Team•Dec 20, 2025•Internal Medicine

Approximately 31.1% of randomized clinical trials (RCTs) approved by ethics committees are discontinued prematurely, with inadequate participant recruitment serving as the primary cause in 45.4% of those cases.
A significant transparency gap exists: while 92.3% of industry-sponsored trials made their results publicly available, only 66.3% of non-industry trials did the same.
Industry-sponsored trials are approximately three times more likely to avoid discontinuation due to recruitment issues compared to academic or investigator-initiated trials (OR 0.32).
While nonregistration has improved (only 5.8% of trials remained unregistered), the failure to publish results remains a critical source of research waste, particularly in the academic sector.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Approximately 31.1% of randomized clinical trials (RCTs) approved by ethics committees are discontinued prematurely, with inadequate participant recruitment serving as the primary cause in 45.4% of those cases.
A significant transparency gap exists: while 92.3% of industry-sponsored trials made their results publicly available, only 66.3% of non-industry trials did the same.
Industry-sponsored trials are approximately three times more likely to avoid discontinuation due to recruitment issues compared to academic or investigator-initiated trials (OR 0.32).
While nonregistration has improved (only 5.8% of trials remained unregistered), the failure to publish results remains a critical source of research waste, particularly in the academic sector.